What Kynam Capital Management, LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1907884 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 8.1M |
| ±0% |
| $176M |
| 9.7% |
PCVXVaxcyte, Inc. | 2.9M | ±0% | $169.9M | 9.4% |
COGTCogent Biosciences, Inc. | 3.7M | −9.2% | $141.9M | 7.8% |
VERAVera Therapeutics, Inc. | 2.9M | −15.0% | $124M | 6.9% |
VRDNViridian Therapeutics, Inc. | 6.5M | +175.6% | $118.6M | 6.6% |
TVTXTravere Therapeutics, Inc. | 2M | +27.5% | $113.6M | 6.3% |
BEAMBeam Therapeutics Inc. | 2.8M | −22.9% | $97.5M | 5.4% |
URGNUroGen Pharma Ltd. | 2.4M | +8.3% | $89.6M | 5% |
LEGNLegend Biotech Corp | 3M | +90.4% | $86.7M | 4.8% |
CTMXCytomX Therapeutics, Inc. | 21.7M | +44.6% | $81.4M | 4.5% |
RLAYRelay Therapeutics, Inc. | 3.3M | +131.7% | $61.7M | 3.4% |
CGEMCullinan Therapeutics, Inc. | 3.1M | ±0% | $56.7M | 3.1% |
MBXMBX Biosciences, Inc. | 934.8K | ±0% | $51.6M | 2.9% |
IMCRImmunocore Holdings plc | 1.4M | +55.4% | $43.7M | 2.4% |
NRIXNurix Therapeutics, Inc. | 1.2M | ±0% | $29M | 1.6% |
STROSutro Biopharma, Inc. | 872.6K | ±0% | $29M | 1.6% |
BCRXBiocryst Pharmaceuticals Inc | 2.5M | −55.6% | $25.2M | 1.4% |
PHVSPharvaris N.V. | 661.8K | +3.3% | $22.9M | 1.3% |
SMMTSummit Therapeutics Inc. | 1.2M | New | $17.5M | 1% |
PRLDPrelude Therapeutics Inc | 2.4M | +51.6% | $12.9M | 0.7% |
INSMINSMED Inc | 100K | New | $10.7M | 0.6% |
BNRBurning Rock Biotech Ltd | 1.2M | +0.9% | $10.5M | 0.6% |
GERNGeron Corp | 6.8M | ±0% | $8.8M | 0.5% |
AMRNAmarin Corp PLC | 533K | +12.8% | $8.5M | 0.5% |
ALECAlector, Inc. | 3.8M | +90.4% | $7.7M | 0.4% |
PBLSParabilis Medicines, Inc. | 250K | New | $6.8M | 0.4% |
CRBUCaribou Biosciences, Inc. | 2.5M | ±0% | $4.4M | 0.2% |
PRQRProQR Therapeutics N.V. | 1.6M | ±0% | $2.9M | 0.2% |
CADLCandel Therapeutics, Inc. | 96.7K | −51.6% | $996.4K | 0.1% |
ENGNenGene Therapeutics Inc. | 457.9K | New | $792.1K | 0.1% |
TRAWTraws Pharma, Inc. | 84.4K | New | $71.2K | 0.1% |
